Abstract: The present invention relates to a method of producing coloured carrier particles which comprises which comprises: a) dispersing a pigment in aqueous solution, b) adding soda waterglass, c) precipitating SiO2 and the pigment onto the carrier particles by lowering the pH value. Using the methods according to the invention it is possible to obtain colorations and coloured substrates that have surprisingly good light-fastness properties.

Abstract: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.

Abstract: A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 mVg can be conveniently compressed into a tablet without generating capping and sticking problems, and a tablet comprising said fused solid dispersion can maintain an uniform release rate over a prolonged time when orally administered.

Abstract: Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed throughout the particles, wherein the active material(s) is capable of being released from said particles, and the active material(s) in said particles is substantially protected from degradation until release of the active material(s) from the particles.

Abstract: The invention provides novel pellets adapted for biologically active preparations and a novel process for preparing said pellets. The novel pellets are adapted for use in the delivery of a biologically active agent. The pellets have an inner zone comprising a plurality of micropellets which are bound together to form a pellet when the micropellets are dispersed in a matrix of an inert pharmaceutical excipient, a biologically active agent and optionally having an outer zone comprising a surface layer comprising a pharmaceutical excipient with or without a biologically active agent. The pellets will have an arcuate surface due to the manner in which they are formed.

Abstract: A physiologically acceptable composition, especially a cosmetic composition, comprising a liquid fatty phase comprising at least one silicone oil, structured with a polymer with a weight-average molecular mass ranging from 500 to 500 000, comprising at least one moiety comprising: at least one polyorganosiloxane group comprising from 1 to 1 000 organosiloxane units in the chain of the moiety of in the form of a graft, and at least two groups capable of establishing hydrogen interactions, the polymer being solid at room temperature and soluble in the liquid fatty phase at a temperature of from 25 to 250° C., solid particles and at least one amphiphilic silicone.

Abstract: The invention describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, in a composition for non-medical treatment of the skin, for example as a deodorant. The invention also describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, for manufacturing of a pharmaceutical preparation for treatment of skin related conditions and diseases, as skin infections. The hydrophobic zeolite is especially selected from that group that comprises silicalite, or hydrophobic ZMS-5, hydrophobic mordenite and hydrophobic zeolite Y.

Abstract: A micelle formable from at least one nanotube in a process of self-assembly, the nanotube comprising an amphophilic nanotube (2, 8, 14) made from one or more species selected from the group of carbon, silicon, a noble metal, silicon dioxide and titanium dioxide. A part of the nanotube (2, 8, 14) is functionalised and a surfactant molecule or emulsifying agent is attached to the functionalised part. The nanotube (2, 8, 14) may have magnetic properties. A therapeutic agent may be incorporated in the micelle. The micelle may be coated to form a capsule (24). The capsule (24) can be introduced to the human or animal body for treatment of tumors or targeted drug delivery when a magnetic field or near-IR radiation is applied.

Abstract: The present invention relates to packaged oral delivery systems for delivery of actives into the oral cavity. In particular, the packaged pharmaceutical product contains a complexate including a complexing agent and an active, an oral delivery system for delivery of the complexate and a package for containing the oral delivery system. The package includes indicia associated therewith. The indicia identifies the complexate as the active ingredient contained in the oral delivery system, which is as a regulatory approvable chemical entity. The present invention also relates to methods of labeling, pricing, marketing and satisfying governmental regulations for such packaged pharmaceutical products.

Abstract: The present invention relates to packaged orally consumable film dosage units for delivery of actives into the oral cavity. In particular, the packaged pharmaceutical product contains a complexate including a complexing agent and an active, an orally consumable film for delivery of the complexate and a package for containing the orally consumable film. The package includes indicia associated therewith. The indicia identifies the complexate as the active ingredient contained in the film, which is as a regulatory approvable chemical entity. The present invention also relates to methods of labeling, pricing, marketing and satisfying governmental regulations for such packaged pharmaceutical products.

Abstract: The present invention relates to ceramic precursor material exhibiting injectability arid properties that make the material suitable as a carrier material used in drug delivery. According to the invention this is accomplished by selecting a microstructure based on pre-reacted phases and after injection established phases, which contain anti-infective and/or anti-inflammatory drugs. The present invention also relates to a cured ceramic material and a method of manufacturing said cured material. The precursor and the cured ceramic material according to the present invention can suitably be used for filling orthopaedic cavities and other bone voids.

Abstract: Chitosan silicon dioxide coprecipitate composition, method of production thereof, pharmaceutical composition comprising the chitosan silicon dioxide coprecipitate composition and use of the chitosan silicon dioxide coprecipitate composition for manufacturing a sustained or immediate release formulation.

Abstract: Malodor free skin care compositions are described. The skin care compositions comprise an adsorbable solvent and an insoluble particle in an adsorbable solvent-insoluble particle complex. The complex is suitable to adsorb components with malodor to yield a skin care composition free of offensive odors like those generated from the oxidation of conjugated linoleic acid.

Abstract: The invention relates to the field of solid medicaments that are intended for the oral administration of active ingredients. The aim of the invention is to prevent the improper use of solid, oral medicaments for any user other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characturised in that it comprises: A) at least one caking agent; and B) at least one viscosifying agent, such as to prevent the misuse thereof.

Abstract: Compressible solid tablets comprising from 20 to 38 wt % of an oily or viscous liquid, from 50 to 70 wt % of a cellulose polymer and from 2 to 15 wt % of an hydrophobic coating compound, wherein said particles size is 180 microns or less. For example, the oily or viscous liquid may consist of plant oils or surfactants such as cocamide DEA, cocoamide propyl betaine and or mixtures thereof. The cellulose polymer may be carboxy methyl cellulose, microcrystalline cellulose or mixtures thereof. The coating hydrophobic composition may be silicon dioxide, calcium orthophosphate, magnesium carbonate, aluminum oxide. Compressible solid particles are also disclosed which comprise from 50 to 70 wt % of a crystalline alcohol, from 25 to 45% of a cellulose polymer and from 5 to 18 wt % of a coating hydrophobic compound. For example, the crystalline alcohol may be a polyol such as xylitol, isomaltose, sorbitol, maltitol, starch hydrolysate; a terpene such as thymol, carvacrol or menthol.

Abstract: The disclosure relates to cosmetic compositions, including makeup and care compositions for the skin, comprising at least one fatty phase comprising at least one volatile oil, at least one organic filler and at least one mineral filler, wherein the composition has: a haze index, (Th?Td)/Th*100, of greater than or equal to 40%, and a transparency index, Th, of greater than or equal to 70%, wherein Th is the hemispheric transmittance of the composition and Td is the direct transmittance of the composition. This composition may be used to mask wrinkles and other defects of the contour of the lips. It may also be used to modify the visual perception of the volume of the part of the body on which it is applied.

Abstract: An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated in a closed capsule assembly. The closed capsule assembly comprises the homeopathic carrier.

Abstract: A composition in the form of a water-in-oil emulsion containing an aqueous phase dispersed in an oily phase, and further containing: (1) at least one silicone emulsifier, (2) at least one hydrophilic polymer chosen from crosslinked acrylic polymers and 2-acrylamido-2-methylpropanesulfonic acid polymers, and (3) at least one silicon-based filler, where the amount of aqueous phase is at least 60% by weight relative to the total weight of the composition. Uses, including moisturizing the skin and attenuating the visible or tactile irregularities of the surface of the skin.

Abstract: Biofunctional nanoprobes are disclosed having nanoscale dimensions enabling the non-destructive penetration of lipid membranes. They are functionalized to perform a bio-chemical process using bio-compatible, porous coating in which enzymes are structurally constrained.

Abstract: The present invention contemplates a dual warming and moisturizing composition comprising a hydrous portion comprising water and an anhydrous portion comprising a zeolite a carrier and a suspending or dispersing agent, wherein the anhydrous portion and the hydrous portion are combined in use to provide warming and moisturizing effects without the addition of external water.

Abstract: Provided are a hybrid of a poorly soluble basic drug and a layered silicate, including a water-soluble basic polymer, and a method of preparing the same. The water-soluble basic polymer may be an aminoalkylmethacrylate copolymer (e.g., Eudragit E 100: a copolymer composed of 1:2:1 ratio of butyl methacrylate, (2,2-dimethylaminoethyl)methacrylate, and methyl methacrylate, Degussa) or polyvinylacetal diethylaminoacetate (AEA). In an oral formulation including the hybrid, a short-term dissolution of the poorly soluble drug can be increased to 90%, thereby increasing drug bioavailability.

Abstract: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Abstract: Gold suspensions with high concentrations of gold, and silver suspensions with high concentrations of silver, are provided. Gold or silver nanoparticles are put into suspension, where the metal nanoparticles are paired with silica. Biocompatible suspensions are one application. Noble metal particles, attached to the surface of silica particles, form a stable, non-agglomerated suspension due to the steric and repulsive properties of the silica particles. The noble metal particles are prepared by activating the surface of the silica particles and erecting nucleation sites for metal particle growth, and then growing the metal particles at the nucleation sites through a reduction procedure.

Abstract: Solid compositions applicable to the human skin and gellable on contact with water. These compositions are prepared in the form of a flexible solid film and can be used for cosmetic and/or therapeutic purposes. The compositions contain hyaluronic acid, a very fine inert powder and a small quantity of water as essential components.

Abstract: A pharmaceutical preparation comprising: a) a core with an active ingredient and with an organic acid and/or the salt of an organic acid; and b) a coating which envelops the core and which comprises a polymer content of (meth)acrylate copolymers which have not more than 15% by weight of cationic or anionic groups, and which comprises at least 60% by weight of a (meth)acrylate copolymer which is composed of free-radically polymerized units of 93 to 98% by weight C1- to C4-alkyl esters of acrylic or of methacrylic acid and 7 to 2% by weight (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, wherein the active ingredient has a solubility in water of at least 10 g/l at 20° C. and the coating comprises silicon dioxide particles having an average particle size in the range from 1 to 50 ?m.

Abstract: A compositions for external use comprising succinoglucan and a water-swelling clay mineral, which is useful particularly as cosmetics. The composition can give a novel feeling upon use which satisfies the diversified requirements by consumers and is excellent in long-term stability.

Abstract: It discloses a facial treatment mask that can be applied directly on the user's skin, with improved organoleptic properties, along with a process for preparing the product that serves as a base for the mask. Said product consists of the mixture of two separate phases, immediately prior to application. Each phase consists of a series of ingredients which give them their appearance of a suspension and gel respectively, so that when combined together, they form a genuine emulsion. The process for preparing each phase includes various steps of mixing and combining their respective ingredients, with the help of blending and kneading devices that operate for pre-determined periods of time. The application is conducted within a maximum period of approximately 4 to 5 minutes, and the polymerisation or setting is achieved within a minimum time frame of approximately 15 minutes.

Abstract: The present invention relates to a method of abating hydrogen sulfide gas emitted by or generated in landfills. Certain embodiments of the present invention relate to contacting hydrogen sulfide gas with Fuller's earth or other carrier materials and metals such as silver, copper, iron, zinc or mixtures thereof, and other components.

Abstract: Cosmetic or dermatological stick preparations, which are finely disperse systems of the water-in-oil type, comprising a) an oil phase which ?comprises from 10 to 70% by weight, based on the weight of the fatty phase, of fatty and/or wax components which melt above a temperature of 40° C., b) a water phase, c) at least one modified phyllosilicate which exhibits both hydrophilic and also lipophilic properties, which thus has amphiphilic character and positions itself at the water/oil interface, and d) at most 0.5% by weight of one or more emulsifiers and method for their preparation.

Abstract: The present invention relates to a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: Clostridium-like species, Prevotella-like species, Bacteroides-like species, Enterococcus-like species, Selenomonas species, non-dextran slime producing Streptococcus species and non-slime producing lactic acid bacterial isolates.

Abstract: An objective of the present invention is to provide a method for producing cosmetic products capable of improving a touch of cosmetic products containing powder and exerting the function of the powder sufficiently. In order to accomplish the objective described above, a method for producing cosmetic products according to the invention comprises a use of a media-agitating mill to disperse powder components and oil components or aqueous components. A method for producing cosmetic products according to the invention is applied to powdery cosmetic products, oily cosmetic products, emulsified cosmetic products and lipsticks. A method for producing cosmetic products involving a step for imparting a particle with hydrophobicity using a media-agitating mill is also provided. Furthermore, a method for producing cosmetic products using hydrophobicity-imparted powdery dispersion containing organically-denatured clay mineral is provided.

Abstract: This invention refers to the preparation for elimination of neuropathies in diabetes. The preparation contains a combination of minerals and plant extracts. By its ionic exchange, the invention reduces considerably the process of apoptosis of nerve-cells, eliminates the process of activation of the immunologic system, and stops the immunologic reaction of auto-destruction of nerve-cells. Depositing of immunoglobulin on axons is absent, and neuropathic pain disappears. Furthermore, the preparation reduces the activity of free radicals, improves the regulation of glycemia and improves the recovery of axons which are already damaged.

Abstract: The invention concerns a composition containing a high level of Vitamin E in encapsulated form, preferably as beadlets or spray dried, and a high level of silicates. The composition is compressible into tablets or caplets that do not leach out Vitamin E into the tablet matrix during compression and/or storage. The composition preferably contains vitamins and minerals in doses optimized for cardiovascular health.

Abstract: Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Abstract: A storage-stable biocidal aerated gel composition comprises from 30 to 97% by weight of water, from 0.2 to 5% by weight of a gelling agent selected from xanthan gum, sodium alginate and neutralised carboxyvinyl polymer from 2 to 5% by weight of a fine particulate, hydrophobic silicone-treated silica having a surface area of from 80 to 300 m2/g and from 0.004 to 20% by weight of a biocide which said composition is in the form of fine particles of an aqueous gel containing the water, gelling agent and the biocide, the surfaces of which fine particles are coated with a coating of the finely particulate hydrophobic silica. The biocidal aerated gel composition can be used to control pests using one or more appropriate biocides in the composition.

Abstract: The invention relates to novel phthalamides of the formula (I) in which disclosure. The invention further relates to a process for preparing these compounds and their use for controlling pests.

Abstract: The invention relates to a process for preparing a soft tablet capable of being chewed or disintegrated in the oral cavity. The tablet is prepared by forming a tablet having a friability of less than about 2% from a mixture comprising a pharmaceutically active ingredient, an excipient in the form of a hydrate, and a water-swellable excipient, and then applying sufficient energy, preferably in the form of heat, to the tablet for a sufficient time to decrease the hardness of the tablet by at least about 20%.

Abstract: The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions, and methods of use thereof.

Abstract: A thermal adhesion granulation process for preparing direct tabletting formulations or aids is disclosed. The process comprises the step of subjecting all or part of a mixture comprising: A) from about 5 to about 99% by weight of one or more diluent excipients and/or from 0 to about 99% by weight of a pharmaceutically active ingredient; B) from about 1 to about 95% by weight of a binder excipient; optionally with, C) from 0 to about 10% by weight of a disintegrant excipient; to heating at a temperature in the range of from about 30 to about 130° C. under the condition of low moisture or low content of a pharmaceutically-acceptable organic solvent in a closed system under mixing by tumble rotation until the formation of granules.

Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.

Abstract: Coated powder is obtained by applying a material having a refractive index of 1.9 to 3.1 to powder having a refractive index of 1.3 to 1.8 as a core and further applying a material having a refractive index of 1.3 to 1.8 to the coated core. When this powder is used for cosmetics or paints, natural coloring can be accomplished without deteriorating lightness because a screening effect is not high.

Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.

Abstract: Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100° C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.

Abstract: Novel emulsion compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel emulsion compositions of the present invention include drug-containing emulsions adsorbed onto solid particles which may be further formulated into solid dosage forms, methods of preparing such emulsion compositions and their uses thereof. The emulsion compositions and their dosage forms improve the drug-load and the bioavailability of a wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.

Abstract: The invention relates to hair compositions packaged in aerosol form and comprising, in a cosmetically acceptable medium, a polycondensate, such as a multiblock polymer, comprising at least one polyurethane and/or polyurea unit, at least one polyol, an organic solvent, and a propellant gas. The invention is also directed towards a process for shaping or maintaining the hairstyle, comprising the use of these compositions, as well as to their use for the manufacture of hair products, in order to maintain or shape the hairstyle.

Abstract: Ectoparasites, such as fleas, ticks, mites and lice, are removed from a human or animal host after applying a composition that causes the temperature of the treated area to become higher or lower than normal. In one embodiment, treatment is effected by applying a composition that releases heat when contacted with water. The elevated or decreased temperature immobilizes the parasites and facilitates their mechanical removal, such as by combing.

Abstract: A coating for masking or reducing the detectable presence of certain characteristic odor or odors, taste or tastes of pharmaceutical preparations, particularly Valerian extracts, is described. The coating comprises from one to three coating compartments, in any combination or as a single-layer amalgam. The first coating compartment comprises a hydroxyalkyl cellulose and an anti-tackiness agent. The second coating compartment may comprise a sugar and at least one anti-tackiness agent. The third coating compartment may comprise a methacrylate copolymer, a hydroxyalkyl cellulose and an anti-tackiness agent.

Abstract: Disclosed herein is an aqueous suspension of insecticidally active compounds comprising a solid active compound applied as a coating to an inorganic carrier and auxiliaries, water and glycerol.

Abstract: A cosmetic composition comprising a lipophilic clay gel and a hydrophilic clay gel. The two gels are combined or formed in situ to create a gel matrix. This matrix functions like an emulsion to deliver water and oil to the skin or other surface, but can be substantially free of surfactants, emulsifiers and waxes. A method for the preparation of a clay gel matrix is also revealed.

Abstract: The present invention includes a cosmetic formulation. The cosmetic formulation comprises a plurality of spheres having a first desiccated volume and having a second hydrated volume. The hydrated volume is greater than the desiccated volume.